HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Distinct mutational pattern of myelodysplastic syndromes with and without 5q- treated with lenalidomide.

AuthorsVera Adema, Laura Palomo, Andrea Toma, Olivier Kosmider, Francisco Fuster-Tormo, Rocío Benito, Rocío Salgado, Esperanza Such, María José Larrayoz, Blanca Xicoy, Jesus Maria Hernandez-Sanchez, Paolo Maietta, Alexander Neef, Michaela Fontenay, Mariam Ibañez, Maria Diez-Campelo, Sara Alvarez, Jaroslaw P Maciejewski, Pierre Fenaux, Francesc Sole
JournalBritish journal of haematology (Br J Haematol) Vol. 189 Issue 4 Pg. e133-e137 (05 2020) ISSN: 1365-2141 [Electronic] England
PMID32147816 (Publication Type: Letter, Research Support, Non-U.S. Gov't)
Chemical References
  • Lenalidomide
Topics
  • Humans
  • Lenalidomide (pharmacology, therapeutic use)
  • Mutation
  • Myelodysplastic Syndromes (drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: